Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5.
The role of surgery for first relapse locally recurrent retroperitoneal sarcoma (RPS-LR1) is uncertain. We report outcomes of the largest RPS-LR1 series and propose a new prognostic nomogram.
Patients with consecutive RPS-LR1 without distant metastases who underwent resection at 22 centers (2002-2011) were included. Endpoints were disease-free and overall survival (DFS, OS) and crude-cumulative-incidence (CCI) of local/distant recurrence from second surgery. Nomograms predicting DFS and OS from second surgery were developed and validated (calibration plots); discrimination was assessed (Harrell C index).
Of 684 patients identified, full prognostic variable data were available for 602. Initial surgery for primary RPS was performed at our institutions in 188 patients (31%) and elsewhere in 414 (69%). At a median follow-up of 119 months [Interquartile range (IQR), 80-169] from initial surgery and 75 months (IQR 50-105) from second surgery, 6-year DFS and OS were 19.2% [95% confidence interval (CI), 16.0-23.0%] and 54.1% (95% CI, 49.8-58.8%), respectively. Recurrence patterns and survival probability were histology-specific, with liposarcoma subtypes having the highest 6-year CCI of second local recurrence (LR, 60.2%-70.9%) and leiomyosarcoma (LMS) having higher 6-year CCI of distant metastasis (DM, 36.3%). Nomograms included age at second surgery, multifocality, grade, completeness of second surgery, histology, chemotherapy/radiotherapy at first surgery, and number of organs resected at first surgery. OS and DFS nomograms showed good calibration and discriminative ability (C index 0.70 and 0.67, respectively).
We developed nomograms to predict DFS and OS for patients undergoing RPS-LR1 resection. Nomograms provide individualized, disease-relevant estimations of survival for RPS-LR1 patients and assist in clinical decisions.
对于首次局部复发性腹膜后肉瘤(RPS-LR1)的手术治疗作用尚不确定。我们报告了最大的 RPS-LR1 系列的结果,并提出了一种新的预后列线图。
纳入 22 个中心(2002-2011 年)连续接受手术治疗且无远处转移的 RPS-LR1 患者。研究终点为无病生存(DFS)和总生存(OS),以及第二次手术后局部/远处复发的粗累积发生率(CCI)。从第二次手术中开发和验证了预测 DFS 和 OS 的列线图(校准图);评估了区分能力(Harrell C 指数)。
在确定的 684 名患者中,有 602 名患者的完整预后变量数据可用。188 名患者(31%)在我们的机构进行了原发性 RPS 的初始手术,而 414 名患者(69%)在其他机构进行了手术。从初始手术到第二次手术的中位随访时间为 119 个月(IQR,80-169)和 75 个月(IQR,50-105),6 年的 DFS 和 OS 分别为 19.2%(95%CI,16.0-23.0%)和 54.1%(95%CI,49.8-58.8%)。复发模式和生存概率具有组织学特异性,脂肪肉瘤亚型的第二次局部复发的 6 年 CCI 最高(60.2%-70.9%),而平滑肌肉瘤(LMS)的远处转移(DM)6 年 CCI 较高(36.3%)。列线图包括第二次手术时的年龄、多灶性、分级、第二次手术的完整性、组织学、第一次手术时的化疗/放疗以及第一次手术切除的器官数量。OS 和 DFS 列线图显示出良好的校准和区分能力(C 指数分别为 0.70 和 0.67)。
我们开发了用于预测接受 RPS-LR1 切除术患者的 DFS 和 OS 的列线图。列线图为 RPS-LR1 患者提供了与疾病相关的生存个体化估计,并有助于临床决策。